Related Experiment Video
Updated: Jan 12, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Synergistic approach utilizing bioinformatics, machine learning, and traditional screening for the identification of
Yang Lu1, Bizhi Li2, Xiaoli Zheng3
1Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, 310015, China. luyang@hzcu.edu.cn.
Abstract:
The overexpression or activation of C-terminal Src kinase (CSK) has been recognized as a pivotal factor in the progression of hepatocellular carcinoma (HCC), positioning CSK as a promising therapeutic target. Despite this potential, no CSK-specific inhibitors have been developed for HCC treatment to date. Addressing this gap, our study established a robust virtual screening protocol that integrates energy-based screening techniques with machine learning methodologies. Through this systematic approach, we identified a novel compound, 6, exhibiting potent CSK inhibitory activity, as evidenced by an IC50 value of 675 nM in a homogeneous time-resolved fluorescence (HTRF) bioassay. Notably, this compound demonstrated significant growth inhibition in Huh-7 and Huh-6 cell lines, along with the suppression of clone formation. To elucidate the underlying mechanism, we conducted molecular dynamics simulations, which revealed critical binding interactions between compound 6 and CSK. Specifically, residues Phe333 and Met269 were found to play essential roles in mediating these interactions, providing valuable insights into the compound's mode of action.
Insights
A novel compound, 6, shows potent C-terminal Src kinase (CSK) inhibition, offering a potential new therapy for hepatocellular carcinoma (HCC). This discovery addresses the lack of specific CSK inhibitors for HCC treatment.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- C-terminal Src kinase (CSK) overexpression/activation is crucial in hepatocellular carcinoma (HCC) progression.
- CSK is a potential therapeutic target for HCC, but specific inhibitors are lacking.
Purpose of the Study:
- To identify novel, specific CSK inhibitors for HCC treatment.
- To develop and validate a virtual screening protocol for drug discovery.
Main Methods:
- Integrated virtual screening combining energy-based methods and machine learning.
- Homogeneous time-resolved fluorescence (HTRF) bioassay to determine inhibitory activity (IC50).
- Cell-based assays for growth inhibition and clone formation.
- Molecular dynamics simulations to elucidate binding mechanisms.
Main Results:
- A novel compound, designated 6, was identified with potent CSK inhibitory activity (IC50 = 675 nM).
- Compound 6 significantly inhibited growth and clone formation in HCC cell lines (Huh-7, Huh-6).
- Molecular dynamics revealed key interactions between compound 6 and CSK, involving residues Phe333 and Met269.
Conclusions:
- Compound 6 represents a promising lead for developing specific CSK inhibitors against HCC.
- The identified binding interactions provide a basis for further drug optimization.
- The virtual screening protocol is effective for identifying potential kinase inhibitors.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...